Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 17Carcinoma, Hepatocellular 5Recurrence 4Neoplasms, Plasma Cell 4Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Liver Neoplasms 3Sarcoma 2NSCLC 2Lymphoma, Large B-Cell, Diffuse 2Esophageal Neoplasms 2Waldenstrom Macroglobulinemia 1Stomach Neoplasms 1Pathologic Complete Response 1Osteosarcoma 1Neoplasms, Second Primary 1Neoplasms 1Melanoma 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Large Granular Lymphocytic 1Leiomyosarcoma 1Kidney Neoplasms 1Immunoglobulin Light-chain Amyloidosis 1Immunoblastic Lymphadenopathy 1Glioblastoma 1Extrapancreatic Neuroendocrine Tumor 1Colonic Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Trastuzumab 2toripalimab 1pyrotinib 1Vinblastine 1Transurethral Resection of Bladder 1Thalidomide 1TP protocol 1Sodium Chloride 1Radiotherapy, Intensity-Modulated 1Radiotherapy 1Positron Emission Tomography Computed Tomography 1Paclitaxel 1Neoadjuvant Therapy 1Metformin 1Magnetic Resonance Imaging 1Immunohistochemistry 1Esophagectomy 1Endoscopy 1Dynamic Contrast Enhanced Magnetic Resonance Imaging 1Diffusion Magnetic Resonance Imaging 1Dexamethasone 1Decitabine 1Cytarabine 1Cisplatin 1Chemoradiotherapy 1Cell-Free Nucleic Acids 1Carboplatin 1Bortezomib 1Blood Specimen Collection 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Pathologic Complete Response × Thalidomide × Clear all
NCT01134484 2012-07-20

VELCADE-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) Incorporated Into Double Autotransplantation for Untreated Multiple Myeloma (MM)

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Phase 3 Unknown
480 enrolled
Plasma cell

Pathologic Complete Response, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡